Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

被引:7
作者
Guancial, Elizabeth A. [1 ]
Kilari, Deepak [2 ]
Xiao, Guang-Qian [3 ]
Abu-Farsakh, Sohaib H. [3 ]
Baran, Andrea [4 ]
Messing, Edward M. [5 ]
Kim, Eric S. [1 ]
机构
[1] Univ Rochester, Dept Med, James P Wilmot Canc Inst, Rochester, NY USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[3] Univ Rochester, Dept Pathol, Rochester, NY 14627 USA
[4] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA
[5] Univ Rochester, Dept Urol, Rochester, NY USA
关键词
COPPER TRANSPORTER CTR1; UROTHELIAL CARCINOMA; EXPRESSION; METHOTREXATE; GEMCITABINE; VINBLASTINE; DOXORUBICIN; CYSTECTOMY; ERCC1;
D O I
10.1371/journal.pone.0155503
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Platinum (Pt)-based chemotherapy is the standard of care for muscle-invasive bladder cancer (MIBC). However, resistance is a major limitation. Reduced intratumoral drug accumulation is an important mechanism of platinum resistance. Our group previously demonstrated a significant correlation between tissue Pt concentration and tumor response to Pt-based neoadjuvant chemotherapy (NAC) in lung cancer. We hypothesized that increased Pt concentration in radical cystectomy (RC) specimens would correlate with improved pathologic response to Pt-based NAC in MIBC. Methods A cohort of 19 clinically annotated, archived, fresh frozen RC specimens from patients with MIBC treated with Pt-based NAC was identified [ypT0 (pathologic complete response, pCR), N = 4; <= ypT1N0M0 (pathologic partial response, pPR), N = 6; >= ypT2 (minimal pathologic response/progression), N = 9)]. RC specimens from 2 patients with MIBC who did not receive NAC and 1 treated with a non-Pt containing NAC regimen were used as negative controls. Total Pt concentration in normal adjacent urothelial tissue and bladder tumors from RC specimens was measured by flameless atomic absorption spectrophotometry. Results Total Pt concentration in normal urothelium differed by tumor pathologic response (P = 0.011). Specimens with pCR had the highest Pt concentrations compared to those with pPR (P = 0.0095) or no response/progression (P = 0.020). There was no significant difference in Pt levels in normal urothelium and tumor between pPR and no response/progression groups (P = 0.37; P = 0.25, respectively). Conclusions: Our finding of increased intracellular Pt in RC specimens with pCR following NAC for MIBC compared to those with residual disease suggests that enhanced Pt accumulation may be an important determinant of Pt sensitivity. Factors that modulate intracellular Pt concentration, such as expression of Pt transporters, warrant further investigation as predictive biomarkers of response to Pt-based NAC in MIBC.
引用
收藏
页数:10
相关论文
共 31 条
[11]   Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum [J].
Dinney, Colin P. N. ;
Hansel, Donna ;
McConkey, David ;
Shipley, William ;
Hagan, Michael ;
Dreicer, Robert ;
Lerner, Seth ;
Czerniak, Bogdan ;
Waldman, Fred ;
Groshen, Susan ;
True, Lawrence D. ;
Petricoin, Emanuel ;
Theodorescu, Dan ;
Hruszkewycz, Andrew ;
Bajorin, Dean .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (08) :1108-1115
[12]   BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer [J].
Font, A. ;
Taron, M. ;
Gago, J. L. ;
Costa, C. ;
Sanchez, J. J. ;
Carrato, C. ;
Mora, M. ;
Celiz, P. ;
Perez, L. ;
Rodriguez, D. ;
Gimenez-Capitan, A. ;
Quiroga, V. ;
Benlloch, S. ;
Ibarz, L. ;
Rosell, R. .
ANNALS OF ONCOLOGY, 2011, 22 (01) :139-144
[13]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[14]   PO stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors [J].
Kassouf, Wassim ;
Spiess, Philippe E. ;
Brown, Gordon A. ;
Munsell, Mark F. ;
Grossman, H. Barton ;
Siefker-Radtke, Arlene ;
Dinney, Colin P. N. ;
Kamat, Ashish M. .
EUROPEAN UROLOGY, 2007, 52 (03) :769-776
[15]  
Kilari D, 2016, ANTICANCER RES, V36, P495
[16]   Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer [J].
Kim, Eric S. ;
Tang, XiMing ;
Peterson, Derick R. ;
Kilari, Deepak ;
Chow, Chi-Wan ;
Fujimoto, Junya ;
Kalhor, Neda ;
Swisher, Stephen G. ;
Stewart, David J. ;
Wistuba, Ignacio I. ;
Siddik, Zahid H. .
LUNG CANCER, 2014, 85 (01) :88-93
[17]   Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer [J].
Kim, Eric S. ;
Lee, J. Jack ;
He, Guangan ;
Chow, Chi-Wan ;
Fujimoto, Junya ;
Kalhor, Neda ;
Swisher, Stephen G. ;
Wistuba, Ignacio I. ;
Stewart, David J. ;
Siddik, Zahid H. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) :3345-3352
[18]   Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy [J].
Kim, Kyoung Ha ;
Do, In-Gu ;
Kim, Hyeong Su ;
Chang, Myung Hee ;
Kim, Hyo Song ;
Jun, Hyun Jung ;
Uhm, Jieun ;
Yi, Seong Yoon ;
Lim, Do Hyoung ;
Ji, Sang Hoon ;
Park, Min Jae ;
Lee, Jeeyun ;
Park, Se Hoon ;
Kwon, Ghee Young ;
Lim, Ho Yeong .
APMIS, 2010, 118 (12) :941-948
[19]   Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy [J].
Kim, Miso ;
Ku, Ja Hyeon ;
Kwak, Cheol ;
Kim, Hyeon Hoe ;
Lee, Eunsik ;
Keam, Bhumsuk ;
Kim, Tae Min ;
Heo, Dae Seog ;
Lee, Se-Hoon ;
Moon, Kyung Chul .
PLOS ONE, 2015, 10 (07)
[20]  
Koga H, 2000, INT J ONCOL, V16, P1003